Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Dec 24;17:11485–11503. doi: 10.2147/JIR.S492875

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 Zhou et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Validation of INSIG1 expression in psoriasis through experiments and molecular docking results between INSIG1 and tetrandrine. (A and B) IHC results of INSIG1 expression in the Pso group compared with the Control group in clinical samples (n=20) and (C and D) in in vivo (n=6) experiments (scale bar = 50 μm and 20 μm). (E) mRNA expression level of INSIG1 in the Pso model group compared with the control group in vivo (n=6). (F) Drug sensitivity enrichment analysis of INSIG1. (G and H) Visualization of molecular docking between INSIG1 and tetrandrine. (I) Results of interaction analysis between ligand (tetrandrine) and receptor (INSIG1). Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, compared with the Control group.